Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide Consolidation in APL
NCT00276601Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2004
- Primary completion
- Dec 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute promyelocytic leukemia (APL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Disease-free survival at 5 years and Safety of arsenic trioxide. Started Oct 2004; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00276601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276601.